Trial Profile
Role of potential Biomarkers in the efficacy of glatiramer acetate in subjects with relapsing-remitting multiple sclerosis.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 May 2016
Price :
$35
*
At a glance
- Drugs Glatiramer acetate (Primary)
- Indications Multiple sclerosis
- Focus Biomarker; Pharmacogenomic; Therapeutic Use
- 17 May 2016 New trial record